Effects of danofloxacin dosing regimen on gastrointestinal pharmacokinetics and fecal microbiome in steers
- PMID: 34045586
- PMCID: PMC8160337
- DOI: 10.1038/s41598-021-90647-z
Effects of danofloxacin dosing regimen on gastrointestinal pharmacokinetics and fecal microbiome in steers
Abstract
Fluoroquinolones are a class of antimicrobial commonly used in human medicine, and deemed critical by the World Health Organization. Nonetheless, two formulations are approved for the treatment of respiratory disease in beef cattle. The objective of this study was to determine the gastrointestinal pharmacokinetics and impact on enteric bacteria of cattle when receiving one of the two dosing regimens (high: 40 mg/kg SC once or low: 20 mg/kg IM q48hr) of danofloxacin, a commonly utilized synthetic fluoroquinolone in veterinary medicine. Danofloxacin was administered to 12 steers (age 7 months) fitted with intestinal ultrafiltration devices at two different dosing regimens to assess the gastrointestinal pharmacokinetics, the shifts in the gastrointestinal microbiome and the development of resistant bacterial isolates. Our results demonstrated high intestinal penetration of danofloxacin for both dosing groups, as well as, significant differences in MIC values for E. coli and Enterococcus between dosing groups at selected time points over a 38 day period. Danofloxacin treatment consistently resulted in the Euryarchaeota phyla decreasing over time, specifically due to a decrease in Methanobrevibacter. Although microbiome differences were minor between dosing groups, the low dose group had a higher number of isolates with MIC values high enough to cause clinically relevant resistance. This information would help guide veterinarians as to appropriate dosing schemes to minimize the spread of antimicrobial resistance.
Conflict of interest statement
The authors declare no competing interests.
Figures









Similar articles
-
Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers.PLoS One. 2019 Oct 4;14(10):e0223378. doi: 10.1371/journal.pone.0223378. eCollection 2019. PLoS One. 2019. PMID: 31584976 Free PMC article.
-
Comparison of the Intestinal Pharmacokinetics of Two Different Florfenicol Dosing Regimens and Its Impact on the Prevalence and Phenotypic Resistance of E. coli and Enterococcus over Time.Microorganisms. 2021 Aug 30;9(9):1835. doi: 10.3390/microorganisms9091835. Microorganisms. 2021. PMID: 34576730 Free PMC article.
-
Impact of Low and High Doses of Marbofloxacin on the Selection of Resistant Enterobacteriaceae in the Commensal Gut Flora of Young Cattle: Discussion of Data from 2 Study Populations.Foodborne Pathog Dis. 2017 Mar;14(3):152-159. doi: 10.1089/fpd.2016.2176. Epub 2017 Jan 10. Foodborne Pathog Dis. 2017. PMID: 28072925 Clinical Trial.
-
Impact of fluoroquinolones on human microbiota. Focus on the emergence of antibiotic resistance.Future Microbiol. 2015;10(7):1241-55. doi: 10.2217/fmb.15.40. Epub 2015 Jun 29. Future Microbiol. 2015. PMID: 26119580 Review.
-
Fluoroquinolone resistance of Escherichia coli and Salmonella from healthy livestock and poultry in the EU.J Appl Microbiol. 2012 Feb;112(2):239-45. doi: 10.1111/j.1365-2672.2011.05193.x. Epub 2011 Nov 29. J Appl Microbiol. 2012. PMID: 22066763 Review.
Cited by
-
Effect of Antimicrobial Use in Conventional Versus Natural Cattle Feedlots on the Microbiome and Resistome.Microorganisms. 2023 Dec 14;11(12):2982. doi: 10.3390/microorganisms11122982. Microorganisms. 2023. PMID: 38138126 Free PMC article.
-
Factors associated with antimicrobial resistant enterococci in Canadian beef cattle: A scoping review.Front Vet Sci. 2023 Apr 20;10:1155772. doi: 10.3389/fvets.2023.1155772. eCollection 2023. Front Vet Sci. 2023. PMID: 37152689 Free PMC article.
-
Comparisons of plasma and fecal pharmacokinetics of danofloxacin and enrofloxacin in healthy and Mannheimia haemolytica infected calves.Sci Rep. 2022 Mar 24;12(1):5107. doi: 10.1038/s41598-022-08945-z. Sci Rep. 2022. PMID: 35332195 Free PMC article.
References
-
- Pfizer. Freedom of Information Summary Advocin 2011, NADA 141-207.
-
- U.S. Department of Health and Human Services. Guidance for Industry: Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concerns (2003). https://www.fda.gov/regulatory-information/search-fda-guidance-documents.... Accessed (2019)
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical